A new checkpoint inhibitor targeting PD-L1 is now in a myeloma clinical trial to be tested alone, with pomalidomide, or pomalidomide/dexamethasone. Checkpoint inhibitors take the “brakes” off the immune system so that it can be free to kill the myeloma cells.
Durvalumab has already received fast-track approval by the FDA for bladder cancer for single-agent use. Because blood cancers like multiple myeloma are typically treated with combination therapies, durvalumab is being tested both alone and with other traditional myeloma combinations.
This trial is for relapsed/refractory multiple myeloma patients and will be open in 13 trial sites in the US.
To learn more about how to join this clinical trial, click here:Durvalumab Clinical Trial